Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on BMS-986196 Pharmacokinetics in Healthy Adults
NCT06034899Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 1, randomised, open-label trial of 11c-bms-986196 in multiple sclerosis (MS) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the serum concentration-time curve from time zero to time of last quantifiable concentration at Day 10, Maximum observed serum concentration at Day 10 and 1 more. Planned start Sep 2023; status: withdrawn.
02
Drugs
11c-bms-986196
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06034899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034899.